Up a level |
Austin, James A, Jenkins, Rosalind E, Austin, Gemma M, Glenn, Mark A, Dunn, Karen, Scott, Laura, Lucas, Claire M ORCID: 0000-0001-6674-7535 and Clark, Richard E ORCID: 0000-0002-1261-3299
(2019)
Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells.
BIOCHEMICAL JOURNAL, 476 (15).
pp. 2255-2269.
Clark, Richard E ORCID: 0000-0002-1261-3299, Basabrain, Ammar A, Austin, Gemma M, Holcroft, Alison K, Loaiza, Sandra, Apperley, Jane F, Law, Christopher, Scott, Laura, Parry, Alexandra D, Bonnett, Laura ORCID: 0000-0002-6981-9212 et al (show 1 more authors)
(2021)
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.
CANCERS, 13 (9).
2155-.
Austin, Gemma M, Knight, Katy, Bell, Joanne, Carter, Anthony, Heartin, Earnest, Watson, David, Foroni, Letizia, Christmas, Stephen E, Polydoros, Fotios and Clark, Richard E ORCID: 0000-0002-1261-3299
(2019)
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
BRITISH JOURNAL OF HAEMATOLOGY, 185 (4).
pp. 791-793.